Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

June 4, 2022

Study Completion Date

September 10, 2023

Conditions
Covid19
Interventions
DRUG

Niclosamide

Niclosamide tablets 400 mg 3 times daily for 14 days

DRUG

Placebo

Matched placebo tablets 400 mg 3 times daily for 14 days

Trial Locations (25)

25006

Private Enterprise Private Manufacturing Company Acinus, Kropyvnytskyi

30076

IACT Health - Roswell, Columbus

33126

LCC Medical Reserach Institute, LLC, Miami

33155

Miami Clinical Research, Miami

33606

University of South Florida, Tampa

35209

Central Alabama Research, Birmingham

39600

"Communal Non-Commercial Medical Enterprise Likarnya Prydniprovska", Kremenchuk

41102

"Municipal Non-profit Enterprise City Clinical Hospital # 4 of Dnipro City Council", Dnipro

50003

Yashoda Hospital, Secunderabad

61124

Municipal Non-Profit Enterprise City Clinical Hospital 13 of Kharkiv Regional Council, Kharkiv

75149

SMS Clinical Research LLC, Mesquite

76025

Municipal Non-profit Enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk

77598

Tranquil Research, Webster

83404

Snake River Research, PLLC, Idaho Falls

110060

Sir Ganga Ram Hospital, Nagar

302039

Maharaja Agrasen Superspeciality Hospital, Jaipur, Jaipur

390001

SSG Hospital and Medical Institute, Vadodara

390021

GMERS Medical College and Hospital, Vadodara

411013

Noble Hospital Private Limited, Pune

500055

Malla Reddy Narayana Multispecialty Hospital, Hyderabad

32720-0920

Midland Florida Clinical Research Center, LLC, DeLand

33016-1895

New Generation Medical Research, Hialeah

33155-2805

Westchester General Hospital, Miami

33175-2912

P & S Research, LLC, Miami

33032-8225

Homestead Associates in Research, Homestead Meadows

Sponsors
All Listed Sponsors
lead

Entero Therapeutics

INDUSTRY